Diagnosis, monitoring or prognosis of type 2 diabetes, impaired glucose tolerance or prediabetes
AssigneesServizo Galego De SAúDe, FundacióN PúBlica Galega Instituto De InvestigacióN Sanitaria De Santiago De Compostela, Universidade De Santiago De Compostela
InventorsManuela ALONSO SAMPEDRO, Arturo GONZÁLEZ QUÍNTELA, Francisco GUDE SAMPEDRO
Life of this patent
Estimating the term…
Abstract
The present invention refers to an in vitro method for the diagnosis, monitoring or prognosis of IGT/diabetes or prediabetes; or for screening or selecting patient candidates to be subjected to OGTT, which comprises assessing the amount of a protein, selected from the group consisting of: Retinol-Binding Protein 4 (Rbp), Alpha-1-acid glycoprotein (Agp), fibronectin (FN), and/or Complement factor H (CFH) which is bound to glycosaminoglycans (GAGs).
Claims8
In vitro method for the diagnosis, monitoring or prognosis of Type 2 diabetes (T2D), impaired glucose tolerance (IGT), or prediabetes which comprises assessing the amount of a protein, selected from the group consisting of:
- Retinol-Binding Protein 4, Alpha-1-acid glycoprotein, fibronectin and/or complement factor H which is/are bound to glycosaminoglycans, in a biological sample obtained from the subject, wherein the determination of a higher amount of a protein, selected from the group consisting of:
- Retinol-Binding Protein 4, Alpha-1-acid glycoprotein, fibronectin and/or complement factor H bound to glycosaminoglycans, as compared with a pre-established threshold value determined in subject who are not suffering from diabetes or prediabetes, is an indication that the subject may be suffering from T2D, IGT or prediabetes, or that the subject has a poor prognosis.
In vitro method, according to topic 1, characterized in that it is performed once an oral glucose tolerance test (OGTT) is carried out.
In vitro method for screening or selecting patient candidates to be subjected to OGTT which comprises assessing the amount of a protein, selected from the group consisting of:
- Retinol-Binding Protein 4, Alpha-1-acid glycoprotein, fibronectin and/or complement factor H which is/are bound to glycosaminoglycans, in a biological sample obtained from the patient, wherein the determination of a higher amount of a protein, selected from the group consisting of Retinol-Binding Protein 4, Alpha-1-acid glycoprotein, fibronectin and/or complement factor H which is/are bound to glycosaminoglycans as compared with a pre-established threshold value, is an indication that the patient may be subjected to OGTT.
In vitro method, according to any of the previous claims, wherein the biological samples is blood, plasma or serum.
In vitro use of a protein selected from the group consisting of:
- Retinol-Binding Protein 4, Alpha-1-acid glycoprotein, fibronectin and/or complement factor H which is/are bound to glycosaminoglycans, for the diagnosis, monitoring or prognosis of T2D, IGT or prediabetes;
- or for screening or selecting patient candidates to be subjected to OGTT.
Immunoassay kit comprising antibodies for determining the amount of a protein selected from the group consisting of:
- Retinol-Binding Protein 4, Alpha-1-acid glycoprotein, fibronectin and/or complement factor H bound to GAGs.
Dependencies are inferred from the claim text.